cancer drugs

  • Date: Sep 15, 2017
  • Category: Biotech

CHIPSA Hospital Files Patent On Coley’s Immunotherapy With Checkpoint Inhibitors

CHIPSA Hospital, dedicated to the accelerated development of nontoxic cancer immunotherapies announced today filing of a patent application covering the combination of FDA approved antibodies known as “checkpoint inhibitors” together with Coley Vaccine, a stimulatory of innate immunity. CHIPSA is the only licensed hospital facility (under doctor supervision) treating with the Coley’s Vaccine in North America. The patent was based on animal data using the established B16 melanoma mouse model, as well as patient cases. Continue reading →